New Hope for Migraine Sufferers in England: Atogepant Offers Relief

Suffering from migraines in England? Discover the game-changer: Atogepant! Say goodbye to pain with this groundbreaking relief. Experience relief like never before. Don't miss out

Migraine sufferers in England may soon have a new weapon in their fight against debilitating headaches. The National Institute for Health and Care Excellence (NICE) has recommended atogepant (brand name: Qulipta) for preventing both episodic and chronic migraines.

What is atogepant and how does it work?

• Unlike traditional migraine medications, atogepant is specifically designed to target the root cause of migraines.
• It belongs to a new class of drugs called gepants, which block a protein called CGRP.
• CGRP is believed to play a key role in migraine development. By blocking its receptor, atogepant prevents migraines from forming.
• Atogepant is the first oral daily treatment for both episodic and chronic migraines that works through this mechanism.

Benefits of atogepant:

• Clinically proven: Three clinical trials have shown atogepant to be safe and effective in reducing the frequency of migraine days.
• Convenient: It's a once-daily pill, eliminating the need for injections or multiple medications.
• Safe: Studies have shown atogepant to be well-tolerated with minimal side effects.
• Flexible: It can be stopped quickly if needed.

Who can benefit from atogepant?

This medication is intended for people who experience:

• At least four migraine days per month.
• Unsuccessful treatment with at least three prior preventative medications.

A brighter future for migraine management:

The availability of atogepant offers significant hope for migraine sufferers in England. This new option provides more choice and potentially better quality of life for those struggling with this debilitating condition.